Lanoxicaps

Known as: GlaxoSmithKline Brand 2 of Digoxin 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1977-2010
01219772010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
The recent Review (Membrane transporters in drug development. Nature Rev. Drug Discov. 9, 215–236; 2010)1 by the International… (More)
Is this relevant?
2006
2006
Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may underlie many herb-drug interactions… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
1997
1997
AIMS To study the effect of eprosartan, a nonbiphenyl tetrazole angiotensin II receptor antagonist, on digoxin pharmacokinetics… (More)
  • table 1
Is this relevant?
Review
1997
Review
1997
The goals of therapy for congestive heart failure (CHF) are to improve quality of life and to prolong it. Improvement in patients… (More)
Is this relevant?
1991
1991
The bioavailability of digoxin in solution (Lanoxicaps, 90-100 percent) is superior to that of Lanoxin tablets (60-80 percent) in… (More)
Is this relevant?
1986
1986
The oral absorption of digoxin in tablet form has been reported to be reduced after cancer chemotherapy and radiation therapy… (More)
Is this relevant?
1984
1984
We report a digoxin radioimmunoassay in human urine employing commercially available reagents. The calibration curve has a mean… (More)
Is this relevant?
1981
1981
Ten healthy subjects took each of 6 different solutions of 0.5 mg digoxin in a study of the effect of different solvents on… (More)
Is this relevant?
1978
1978
(1) The mean cumulative urinary digoxin excretion over 8 days was compared in 8 healthy volunteers after single doses of digoxin… (More)
  • table 1
Is this relevant?
1977
1977
1 Twice daily administration of 0.25 mg digoxin tablets (Lanoxin) or of 0.2 mg digoxin in solution in soft gelatin capsules… (More)
Is this relevant?